Use of Specialty Care Versus Standard Retail Pharmacies for Treatment of Hepatitis C

被引:8
|
作者
Cohen, Stanley Martin [1 ]
Kwasny, Mary J. [2 ]
Ahn, Joseph [1 ]
机构
[1] Rush Univ, Med Ctr, Sect Hepatol, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Dept Community & Mental Hlth Nursing & Hlth Syst, Chicago, IL 60612 USA
关键词
adherence; hepatitis C; specialty care pharmacy; standard retail pharmacy; sustained virologic response; INTERFERON-ALPHA-2B PLUS RIBAVIRIN; SUSTAINED RESPONSE; VIROLOGICAL RESPONSE; COMBINATION THERAPY; PATIENT EDUCATION; MULTICENTER TRIAL; VIRUS-INFECTION; DRUG-THERAPY; ADHERENCE; PEGINTERFERON;
D O I
10.1345/aph.1L227
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Treatment for hepatitis C virus (HCV) is associated with significant adverse events. Improved adherence increases the probability of achieving sustained virologic response (SVR). Despite a lack of supporting literature, the use of specialty care pharmacies has increased in recent years in an attempt to improve HCV treatment outcomes. OBJECTIVE: To compare specialty care versus standard retail pharmacies in HCV treatment outcomes, utilization of office resources, and the use of supplemental medications. METHODS: A retrospective chart review was performed at a single academic institution for adults with HCV infection treated between 2001 and 2006. SVR was the primary endpoint. Secondary endpoints included therapy completion rates, HCV treatment dose reductions, additional phone calls and clinic visits, and the use of supplemental medications. RESULTS: One hundred ninety-seven patients were identified (102 standard and 95 specialty care pharmacy). There were no differences in baseline demographics between the groups, except for a higher proportion of African Americans using specialty care pharmacies. Overall SVR was 103/197 (52%). SVR was 57/102 (560%) in the standard pharmacy group and 46/95 (48%) in the specialty care pharmacy group. There were no statistically significant differences with regard to SVR (even after accounting for differences in ethnicity), the use of supplemental medications, additional clinic phone calls and visits required, and the reasons for HCV therapy discontinuation. There was a statistically significantly higher incidence of HCV medication dose reductions in the standard retail pharmacy group (45% vs 28%; p = 0.016). CONCLUSIONS: The use of specialty care pharmacies for the treatment of HCV was not associated with higher SVR rates. Patients using specialty care pharmacies had a lower incidence of interferon and/or ribavidn dose reductions, but there was no difference between the groups in therapy completion rates, use of additional office resources, or use of supplemental medications.
引用
收藏
页码:202 / 209
页数:8
相关论文
共 50 条
  • [1] Comparison of hepatitis C treatment outcomes between primary care and specialty care
    Stanley, Kate
    Bowie, Bonnie H.
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2022, 34 (02) : 292 - 297
  • [2] Linkage to specialty care in the hepatitis C care cascade
    Blanding, Dena P.
    Moran, William P.
    Bian, John
    Zhang, Jingwen
    Marsden, Justin
    Mauldin, Patrick D.
    Rockey, Don C.
    Schreiner, Andrew D.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2021, 69 (02) : 324 - 332
  • [3] Treatment of chronic hepatitis C: The new standard of care for the future
    Chan, Juliana
    FORMULARY, 2011, 46 (08) : 314 - +
  • [4] Impact of health system specialty pharmacies on total cost of care in cancer treatment, a multisite review
    Wink, Scott
    Schroader, Bridgette Kanz
    Giglio, Toni
    Ward, Angela
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (05) : 884 - 892
  • [5] Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study
    Gunn, Jack
    Higgs, Peter
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2020, 16 (09) : 1298 - 1301
  • [6] Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response
    Lubega, Samali
    Agbim, Uchenna
    Surjadi, Miranda
    Mahoney, Megan
    Khalili, Mandana
    LIVER INTERNATIONAL, 2013, 33 (07) : 999 - 1007
  • [7] INPATIENT CARE OF HEPATITIS C PATIENTS ON TELAPREVIR TREATMENT
    Erguel, Bilal
    Filik, Levent
    GASTROENTEROLOGY NURSING, 2014, 37 (01) : 74 - 76
  • [8] Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis
    Kumthekar, Anand
    Shull, Sarah
    Lovejoy, Travis I.
    Morasco, Benjamin J.
    Chang, Michael
    Barton, Jennifer
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (04) : 592 - 598
  • [9] A Comparison of Modified Directly Observed Therapy to Standard Care for Chronic Hepatitis C
    Cioe, Patricia A.
    Stein, Michael D.
    Promrat, Kittichai
    Friedmann, Peter D.
    JOURNAL OF COMMUNITY HEALTH, 2013, 38 (04) : 679 - 684
  • [10] Telaprevir: Changing the standard of care of chronic hepatitis C
    Rajani, A. K.
    Ravindra, B. K.
    Dkhar, S. A.
    JOURNAL OF POSTGRADUATE MEDICINE, 2013, 59 (01) : 42 - 47